TidalSense

"Transforming respiratory care pathways with AI-driven diagnostic and monitoring technologies."

Where it wins

• First non-spirometry, AI-driven diagnostic device to receive CE-marking as a Class 2a medical device under EU MDR for COPD diagnosis [1].
• Delivers rapid, point-of-care diagnosis in under five minutes without specialist training, contrasting with 30-minute, technique-dependent spirometry [2].
• Utilises a patented sensor and over 2.5 million collected breaths to power AI algorithms that detect lung function changes sensitively [1].
• Enables longitudinal monitoring via N-Tidal® Capture, allowing early intervention to prevent exacerbations and reduce hospitalisations [1].

Credibility: CE-marking as Class 2a under EU MDR [1]; clinical trials with over 2.5 million breaths [1]; 99% patient usability agreement in preliminary studies [2].

• Hardware + AI Platform: Sells a handheld medical device (N-Tidal) that collects breath data via a patented sensor and transmits it to a cloud-based AI platform [1].
• Regulated Medical Device: Operates under EU MDR Class 2a certification, ensuring clinical validation and regulatory compliance for diagnostics [1].
• Data-Driven Insights: Leverages over 2.5 million breaths from clinical trials to refine AI algorithms for accurate, near-real-time diagnosis [2].
• Service-Based Delivery: Offers diagnostics as a fully managed service, reducing operational burden on healthcare providers [1].
• Longitudinal Monitoring: Expands revenue through continuous patient monitoring via N-Tidal® Capture, creating recurring value [1].

• HBOX: Provides SaaS-based remote patient monitoring, but lacks a CE-marked, non-spirometry diagnostic device [3].
• Athelas: Focuses on smart solutions for heart rate and blood pressure, not respiratory diagnostics [3].
• Biobeat: Offers body vitals monitoring, but does not specialise in AI-driven respiratory diagnosis [3].
• Aevice Health: Develops wearable respiratory sensors but lacks a CE-marked diagnostic platform [3].
• Propeller Health: Acquired and focused on mobile respiratory management, but does not offer a non-spirometry diagnostic device [3].

Differentiators: TidalSense’s CE-marked, AI-driven, non-spirometry device offers faster, more accurate diagnosis compared to competitors’ monitoring-focused solutions.

• Late and Inaccurate Diagnosis: COPD and asthma are often diagnosed late, leading to preventable hospitalisations and high healthcare costs [1].
• Inefficient Spirometry: Current diagnostic methods are time-consuming, technique-dependent, and uncomfortable for patients [2].
• High Healthcare Costs: Billions are spent on exacerbations and hospitalisations due to undiagnosed or poorly managed respiratory conditions [1].
• Lack of Early Intervention: Absence of longitudinal monitoring tools prevents early detection and management of respiratory diseases [1].
• Stretched Healthcare Systems: Clinicians face increased burden due to inefficient diagnostic processes and high patient volumes [2].

TidalSense’s CE-marked, non-spirometry diagnostic device positions it as a leader in respiratory care innovation, addressing a critical gap in early COPD and asthma diagnosis. The primary risk lies in scaling adoption within primary care and diagnostics providers, which requires overcoming entrenched spirometry practices. The opportunity lies in expanding into longitudinal monitoring via N-Tidal® Capture, creating recurring revenue and deeper patient engagement. The next signal to watch is the company’s ability to secure partnerships with major healthcare systems and pharma companies, which would validate its platform and drive market penetration.

TidalSense should prioritise publishing transparent pricing models to reduce friction for primary care clinics and diagnostics providers considering adoption. Interconnection: This would enhance the revenue model by making the fully managed service more accessible. Expanding clinical trials to include asthma diagnostics alongside COPD would broaden the addressable market and strengthen the value proposition. Interconnection: This aligns with the company’s mission to transform respiratory care pathways for multiple conditions. Developing a clear ROI framework for healthcare systems could accelerate adoption by quantifying cost savings from reduced hospitalisations. Interconnection: This would strengthen the business model by aligning with payer interests. Enhancing patient-facing features in N-Tidal® Capture, such as personalised health insights, could improve retention and engagement. Interconnection: This supports the customer relationships block by fostering long-term patient involvement.